Leerink initiated coverage of Ovid Therapeutics (OVID) with an Outperform rating and $5 price target
TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on OVID:
- Ovid Therapeutics: Promising Pipeline and Strong Financials Justify Buy Rating
- Ovid Therapeutics Reports Q3 2025 Financial Results
- Ovid Therapeutics reports Q3 EPS (17c), consensus (15c)
- Ovid Therapeutics appoints Alexander as CEO, Levin as Executive Chairman
- Ovid Therapeutics (OVID) Q3 Earnings Cheat Sheet